• logoinverso

PERL Grant

PERL is a the largest monocentric research project on 18F-FDG
Positron Emission Radiomics in Lymphoma

Definition

www.perlgrant.it

PERL is a the largest monocentric research project on 18F-FDG Positron Emission Radiomics in Lymphoma, promoted thanks to a dedicated national grant Ricerca Finalizzata
(code GR-2019-12370372), won in 2020 by a dedicated research team at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome (Italy).

The PERL team

Young Nuclear Medicine physicians, Haematologists and Radiotherapists

Experience

National and international experience on clinical and
research activities on PET/CT
in lymphoma

Project PI

Salvatore Annunziata, MD, PhD, Nuclear Medicine physician and head of TracerGLab GSTeP, an institutional research facility dedicated to PET/CT radiopharmaceuticals.

Other personnel

During the project, other personnel will be involved such as a dedicated fellow in TracerGLab GSTeP and a data analyst in Radiomics GSTeP.

.Aims

.One

to investigate if baseline 18F-FDG-PET/CT radiomics could predict progression free survival (PFS) in a large retrospective cohort of patients with high-grade lymphoma.

.Two

to evaluate the prognostic role of PET/CT parameters in term of overall survival (OS).

.Three

to correlate PET/CT parameters with other clinical variables at baseline.

Immagine4

For patients

Today, patients with poor prognosis undergo to the standard first-line treatment, so the risk of under-treatment still remain.
Baseline 18F-FDG PET/CT could drive personalized treatment in patients with high-grade lymphoma, allowing intensified treatment schemes in aggressive disease.

To be informed and involved as patients or patients’ association in PERL and further projects, please follow the instructions on the Contact page.

Immagine6
Immagine7

For institutions
and companies

If informative, the PERL project may have an important impact on the health system and could result in the use of radiomics in the clinical work-up of patients with lymphoma.

Moreover, study may lead to potential funding delivered by public and private organizations at national and international level interested in research about new imaging-derived biomarkers in the personalized medicine in lymphoma.

To be informed and involved as research institutions and companies in further projects, please follow the instructions on the Contact page.

.Contact us

Dr. Salvatore Annunziata, MD, PhD, Nuclear Physician

PERL PI, Head of TracerGLab GSTeP

Email: salvatore.annunziata@policlinicogemelli.it

Dr. Angela Collarino, MD, PhD, Nuclear Physician

PERL co-PI, TracerGLab GSTeP, Direzione Scientifica IRCCS

Email: angela.collarino@policlinicogemelli.it

Dr. Elizabeth Triumbari, MD, Nuclear Physician

PERL fellow, TracerGLab GSTeP

Email: elizabethkatherineanna.triumbari@guest.policlinicogemelli.it

Dr. Luca Boldrini,

Head of Radiomics GSTeP

Email:  luca.boldrini@policlinicogemelli.it

logo111

PERL is a the largest monocentric research project on 18F-FDG
Positron Emission Radiomics in Lymphoma

separatore

Follow us on

Quick Links

separatore
  • HOME
  • ABOUT US
  • RESULTS
  • CONTACT

Contact Info

separatore
  • Address

    Largo Francesco Vito,1 - 00168 Roma RM

  • Mail
Scroll to Top